Literature DB >> 3876989

Interaction between des-Tyr1-gamma-endorphin and HLA class I molecules: serological detection of an HLA-A2 subtype.

F H Claas, J J van der Poel, R Castelli-Visser, J Pool, R B Chen, K Y Xu, J J van Rood.   

Abstract

Preincubation of lymphocytes with des-Tyr1-gamma-endorphin (DT gamma E) inhibits the reaction between some HLA alloantisera and their corresponding antigens. One HLA-A2-specific antiserum was found which could detect a subtype of the HLA-A2 antigen on DT gamma E-treated lymphocytes from some donors. Comparison with the HLA-A2 subtypes as defined by a combination of cytotoxic T lymphocyte typing and biochemistry showed a complete correlation with the previously described HLA-A2.3 subtype.

Mesh：

Substances：

Year:  1985        PMID： 3876989     DOI： 10.1007/bf00430914

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


  15 in total

1.  Differential recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. II. Definition of three HLA-A2 subtypes by CTLs.

Authors:  J J van der Poel; J Pool; E Goulmy; J J van Rood
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

Review 2.  The interaction of drugs and endogeneous substances with HLA class-I antigens.

Authors:  F H Claas; J J van Rood
Journal:  Prog Allergy       Date:  1985

3.  Allo-antibodies to an antigenic determinant shared by HLA-A2 and B17.

Authors:  F Claas; R Castelli-Visser; I Schreuder; J van Rood
Journal:  Tissue Antigens       Date:  1982-05

4.  Subtypes of HLA-B27 detected by cytotoxic T lymphocytes and their role in self-recognition.

Authors:  M H Breuning; C J Lucas; B S Breur; M Y Engelsma; G G de Lange; A J Dekker; W E Biddison; P Ivanyi
Journal:  Hum Immunol       Date:  1982-12       Impact factor: 2.850

5.  Interaction of penicillin with HLA-A and -B antigens.

Authors:  F H Claas; R Runia-van Nieuwkoop; W van den Berge; J J van Rood
Journal:  Hum Immunol       Date:  1982-08       Impact factor: 2.850

6.  HLA restriction of non-HLA--A, --B, --C and --D cell mediated lympholysis (CML).

Authors:  E Goulmy; A Termijtelen; B A Bradley; J J van Rood
Journal:  Tissue Antigens       Date:  1976-11

7.  Biochemical analysis of variant HLA-B27 antigens.

Authors:  H H Mölders; M H Breuning; P Ivanyi; H L Ploegh
Journal:  Hum Immunol       Date:  1983-02       Impact factor: 2.850

8.  Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs.

Authors:  S Kato; P Iványi; E Lacko; B Breur; R Du Bois; V P Eijsvoogel
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

9.  Definition of four HLA-A2 subtypes by CML typing and biochemical analysis.

Authors:  J J van der Poel; H Mölders; A Thompson; H L Ploegh
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

10.  Comparison of one-dimensional IEF patterns for serologically detectable HLA-A and B allotypes.

Authors:  S Y Yang; Y Morishima; N H Collins; T Alton; M S Pollack; E J Yunis; B Dupont
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846
View more
  1 in total

1.  High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population.

Authors:  Yoshiki Itoh; Nobuhisa Mizuki; Tsuyako Shimada; Fumihiro Azuma; Mitsuo Itakura; Koichi Kashiwase; Eri Kikkawa; Jerzy K Kulski; Masahiro Satake; Hidetoshi Inoko
Journal:  Immunogenetics       Date:  2005-11-08       Impact factor: 2.846
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.